mp.weixin.qq.com· 医药速览·· 6 hours agoPickScore67
Roche Licenses Rona Therapeutics ALK7 RNAi Obesity Drug in $1.16 Billion Deal
减肥药进阶，罗氏11.6亿美元押注中国ALK7资产
In brief
Roche has secured a global exclusive license from China's Rona Therapeutics for an RNA interference drug targeting Activin Receptor-Like Kinase 7 (ALK7) to treat obesity and related metabolic diseases. The deal carries a potential total value of $1.16 billion plus sales royalties. It follows GSK's licensing of an ALK7 program from China's Shi'an Biotech in May 2026, marking another billion-dollar entry into this emerging weight-loss target.
Why it matters
Second billion-dollar ALK7 licensing deal by a global pharma into a Chinese asset within months.
Source: mp.weixin.qq.com · mp.weixin.qq.com